An outburst of pneumonia in December, 2019 in Wuhan, China, has now been gritty to be caused by a novel corona virus. Severe Acute Respiratory Syndrome Corona-virus (SARS-CoV) named is allotted for this novel threads. The disease has spread more than 185 countries and regions, with more than 2.05 million confirmed cases and more than 1,34,354 deaths as of April 16, 2020. The pandemic is enduring to spread inspite of worldwide efforts. The SS-RNA virus from the enveloped corona virus family caused SARS (Severe acute respiratory syndrome) which is life threatening viral infection.The spreading of infection is quick in many countries of the world. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are numerous drug trials going on with some positive results. Though, since no vaccine is available, the best way to fight the virus is by preventive measures. In the present research an attempt had been made to find new COVID-19 main protease inhibitor by molecular docking approach. Fexofenadine is an antihistamine that is used to treat the symptoms of seasonal allergies (hay fever) in adults and children. Fexofenadine is also used to treat skin itching and hives caused by a condition called chronic idiopathic urticaria in adults and children at least 6 years old. Fexofenadine was taken as drug which follows Lippinski’s rule of five, thus having very good drug score as well as drug likeness score. The present study reveals that Doxycycline has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.